Researchers in San Diego collaborated with the American Red Cross to enable molecular testing, reducing incidence in the zip codes where screening was offered.
Researchers report this week that HIV-1 can become resistant to CRISPR/Cas9 editing.
Two recent studies confirm that CRISPR/Cas9 can edit and inhibit latent HIV provirus, but one of them hints that the virus can develop resistance to excision.
Researchers used viral repertoire sequencing to characterize an early-stage HIV-neutralizing antibody, an important step toward developing a vaccine.
The firm's dual assay for host antigen to HIV as well as viral RNA was described in a proof-of-principle study earlier this year.
The company'sExatype software is a web-based solution for locating HIV drug resistance mutations using raw NGS data and other functional information.
The firm has improved design of the system for low-resource settings and validated it on clinical chlamydia samples and extracted HIV, Ebola, and dengue samples.
The companies will work to develop an affordable, portable, and easy-to-use HIV quantitative viral load test using Cue's Lab-In-A-Box MDx platform.
In a pilot study involving 230 HIV-infected patients, the researchers tested the implementation of privacy-preserving genetic testing, using homomorphic encryption.
The Collaborative African Genomics Network recently finished its second year of grant funding, hitting many of its milestones, and is already digging into the work for their third year.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.